pre-IPO PHARMA

COMPANY OVERVIEW

Antios Therapeutics is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure viral diseases. Antios is currently developing ATI-2173, aiming to provide chronic hepatitis B infected patients with a curative combination regimen.


LOCATION

  • Atlanta, GA, USA

  • THERAPEUTIC AREAS

  • Infectious Disease

  • WEBSITE

    https://www.antiostherapeutics.com


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    cam-capital delos-capital domain-associates fonds-de-solidarite gra-venture-fund lumira-ventures quantum-vista-capital


    PRESS RELEASES


    Jun 25, 2022

    Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 2a Study; ATI-1428 and ATI-1645 Exhibit Potent Antiviral Activity in a Nonclinical Study


    Jun 8, 2022

    Antios Therapeutics Announces Oral Presentations on ATI-2173, ATI-1428, and ATI-1645 Hepatitis B Virus Programs at the EASL International Liver Congress™ 2022


    Apr 26, 2022

    Antios Therapeutics Announces Notice of Allowance for U.S. Patent on Phosphoramidates for the Treatment of Hepatitis B Virus


    Mar 30, 2022

    Antios Therapeutics' ATI-2173 Demonstrates Suppression of Hepatitis B Virus in Phase 1b and 2a Studies


    Dec 6, 2021

    Antios Therapeutics Announces Presentations on ATI-2173 at Hep DART 2021 Meeting


    For More Press Releases


    Google Analytics Alternative